SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE CRYPTO is actively trending with renewed upward price movement, as its dedicated 'ByteArmy' community rallies around its 'Grok AI dog' origin and deflationary tokenomics, fueling speculation of significant future growth in the AI memecoin sector.

BlackRock Institutional Trust Company N.A. - iShares 7-10 Year Treasury Bond ETF

iShares 7-10 Year Treasury Bond ETF

IEF is trending amidst a highly polarized community debate, as some interpret recent economic data and Federal Reserve actions as a potential catalyst for a "flight to safety" and a fading bearish bond narrative. Conversely, many others remain strongly bearish on longer-duration treasuries, anticipating further yield increases and limited upside for the asset class.

iShares Ethereum Trust (The) - Undivided Beneficial Interest

iShares Ethereum Trust ETF

ETHA is actively discussed amidst recent crypto market volatility and liquidations, with a split in community sentiment between those "buying the dip" for long-term gains and others expecting further downside. Key catalysts like the upcoming Ethereum Fusaka Upgrade and ongoing discussions around institutional ETF staking approvals are driving optimism for its role as foundational infrastructure for tokenized assets.

VanEck ETF Trust - VanEck Retail ETF

VanEck Retail ETF

The VanEck Retail ETF ($RTH) is a focal point for investors as key retail earnings unfold, reflecting evolving consumer spending trends amidst inflationary concerns. Discussions center on the sector's resilience and potential for profit-taking following the intense holiday shopping season.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is experiencing a significant surge after reporting a surprise Q3 profit and raising its full-year outlook, sparking community excitement over potential short squeeze opportunities and a turnaround driven by the company's perceived undervalued real estate assets. Many anticipate continued momentum into the holiday season, though some question the sustainability of the rapid rally for the traditional retailer.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending after its Q4 earnings report delivered a "blowout" performance, significantly beating user growth and profitability estimates, which sparked a substantial rally. Investors are actively debating whether strategic moves like AI integration, new physical book offerings, and recent price hikes signal sustainable long-term growth and pricing power, or if intensifying competition and a reported major data leak will temper its momentum.

TOSHI

TOSHI CRYPTO is trending as the community observes bullish chart patterns like cup and handle formations and anticipates a significant breakout, fueled by general crypto market optimism and its narrative as the "face of Base." Many believe it's poised for a major move as "ALT season" progresses.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is gaining significant attention following its robust Q4 earnings beat and optimistic 2026 outlook, as investors are actively discussing the company's bold strategy to shed 30,000 jobs and reduce low-margin Amazon deliveries to drive profitability and enhance shareholder value.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending due to ongoing reports of competitive takeover bids, including interest from Hapag-Lloyd, after its board rejected a management-led buyout proposal for significantly undervaluing the company. The community is actively debating the potential for a bidding war, substantial special dividends, and a short squeeze, alongside broader discussions on ZIM's strategic importance for Israel amidst government and union opposition to foreign acquisition.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow Jones Industrial Average is trending after recently closing above 50,000 for the first time, fueled by strong earnings from non-tech components and hopes for ongoing economic growth. While many investors are celebrating this upward momentum, others express caution about market overvaluation and lingering concerns over inflation and various geopolitical events.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving Average - Time to Sell?

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above Fifty Day Moving Average - Time to Sell...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat...

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.7% - Here's Why

Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.7% - Should You Sell...

CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February

CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.

<ul class="summary-bullets"><li>The U.S. Food and Drug Administration did not request any additional clinical studies or new patient data, as per the company.</li><li>Capricor now plans to submit the data requested by the FDA in February.</li><li>CEO Linda Marbán said that the company is “pleased” that the FDA requested the clinical study report, adding that the request was expected.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 2% on Tuesday morning after the company said that the U.S. Food and Drug Administration (FDA) has requested more data from its trials of Deramiocel.In July, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-therapeutics-stock-sparks-retail-frenzy-as-traders-hail-best-data-ahead-of-dmd-data-rollout/cLI7F7XRE0P">refused</a> to approve Capricor’s application for Deramiocel for the treatment of Duchenne muscular dystrophy, stating that it does not meet the requirement for substantial evidence of effectiveness, while also expressing the need for additional clinical data. The company said at the time that it intends to meet the FDA’s additional clinical data requirement with a late-stage study and resubmit its application.In December, the company provided the FDA with results from its late-stage HOPE-3 study in which Deramiocel delivered strong signals of benefit for muscle and heart function. However, after reviewing the data, the FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. The agency, however, did not request any additional clinical studies or new patient data, it <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/335/capricor-therapeutics-provides-regulatory-update-on">added.</a><h2 class="st-heading-2">Fresh Timelines</h2>Capricor now plans to submit the new data requested by the FDA in February and expects that the submission will support continued review of its application and address the concerns raised by the FDA in July. &nbsp;CEO of Capricor, Linda Marbán, said that the company is “pleased” that the FDA requested the clinical study report, adding that the request was expected.“Our near-term priority is to address the FDA’s request and continue working collaboratively so that patients with late-stage DMD, who currently have very limited treatment options, may gain access to Deramiocel as soon as possible,” Marbán added.DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.A Stocktwits user voiced optimism for the drug getting approved in the following three to five months.<stembedurl>https://www.stocktwits.com/jamestrade07/message/642322958</stembedurl>Another user voiced hopes for the stock touching as much as $100 by end of year following Deramiocel approval.<stembedurl>https://www.stocktwits.com/haha1978/message/642314942</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 69% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think?

The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. 

Equity

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average - Here's Why

Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Above 50-Day Moving Average - Time to Sell...

Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen

Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.8% - What's Next?

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 7.8% - Here's Why...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat...

Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen

Wall Street Zen raised Capricor Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CAPR News

CAPRCapricor Therapeutics Inc